Gotrade News - Wall Street analysts have refreshed their views on Principal Financial, ResMed, and Equinix as 2026 earnings outlooks firm up. Consensus ratings range from Hold to Strong Buy, with implied upside spanning a wide arc across the three names.
The three reports highlight diverging investor sentiment toward financials, medtech, and data-center real estate. Each name carries distinct catalysts that could reshape positioning into the second half of 2026.
Key Takeaways
- Principal Financial holds a 'Hold' consensus with limited upside near the $101.50 mean target.
- ResMed earns a 'Moderate Buy' rating with 27.3% implied upside despite a 13.6% year-to-date decline.
- Equinix anchors a 'Strong Buy' consensus, outpacing the S&P 500 with 41% year-to-date gains.
Financials And Medtech Diverge On Sentiment
Principal Financial (PFG) trades at $103.85, with a market capitalization of $22.4 billion and a $101.50 mean target. The Street-high price target of $113 implies roughly 8.8% upside from current levels.
According to Barchart, 14 analysts cover PFG with 11 Hold ratings and only two Buy calls. The stock has gained 17.7% year-to-date, ahead of the XLF financial sector ETF.
Q1 2026 adjusted EPS rose 13% year-over-year to $2.17 on $3.5 billion in revenue. Assets under management reached $770.2 billion, while assets under administration climbed to $1.8 trillion.
The insurer also raised its dividend 8% to $0.82 per share, marking 23 consecutive years of increases. Full-year 2026 adjusted EPS is projected at $9.36, a 13.2% increase.
As reported by Barchart, ResMed (RMD) trades at $208.05 with a $30.3 billion market cap. The Moderate Buy consensus spans 20 analysts, including nine Strong Buy ratings.
The mean target of $264.92 implies 27.3% upside, while the Street-high of $340 signals potential 63.4% gains. KeyBanc trimmed its target to $290 from $302 on April 27, retaining its Overweight stance.
RBC Capital Markets raised its target to $321 from $314 on May 1, reiterating an Outperform rating. ResMed has underperformed, down 13.6% year-to-date against the S&P 500's 9.2% advance.
The sleep apnea and COPD device maker has beaten EPS estimates for four straight quarters. Fiscal 2026 diluted EPS is projected to grow 16.5% to $11.13 per share.
On May 19, ResMed announced a partnership with Oura Ring on sleep apnea symptom screening. The collaboration broadens its consumer-health footprint beyond traditional medical-device channels.
Data-Center Leader Anchors Bullish Camp
Per Barchart, Equinix (EQIX) trades at $1,079.79 with a $106.5 billion market cap. The Strong Buy consensus spans 33 analysts, with 23 Strong Buy ratings.
The mean target of $1,200.57 implies 11.2% upside, while the Street-high of $1,350 signals 25% potential gains. Equinix has gained 41% year-to-date, sharply outpacing the S&P 500.
The data-center operator runs 280+ locations across six continents, the largest network of its kind globally. Q1 2026 recurring revenue rose 10% year-over-year, with interconnection revenue up 9%.
Full-year 2026 funds from operations are projected at $37.72 per share, climbing to $41.09 in 2027. The 8.3% FFO growth supports a 1.91% dividend yield and continued capacity expansion.
Equinix has beaten estimates for four consecutive quarters, reinforcing analyst confidence in execution. The stock also tops the Pacer Benchmark Data & Infrastructure Real Estate SCTR ETF (SRVR), which returned 20% year-to-date.
The three reports underscore how rating dispersion can mask differing risk-reward profiles across sectors. Investors weighing exposure may consider near-term catalysts alongside the implied upside in each consensus target.
